{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:55:13Z","timestamp":1775796913177,"version":"3.50.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The elimination of hepatitis C virus (HCV) infection as a public health threat is impossible to achieve without micro-elimination in children. Our study aimed to analyze the use of glecaprevir\/pibrentasvir (GLE\/PIB), one of the pangenotypic options recommended in children, which provides the shortest possible therapy duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>All consecutive children treated with an 8-week GLE\/PIB regimen for chronic HCV infection between 2022 and 2024, whose data were collected retrospectively, were included in the analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The study population consisted of 42 patients with a median age of 10.5 years, mostly girls (61.9%), divided into age ranges of 3\u20135 years, 6\u201311 years and 12\u201318 years, comprising 6, 16 and 20 patients, respectively. Obesity was diagnosed only in the oldest group in as many as 25% of the children. Other comorbidities were present in 2 patients\u2014kidney disease and bronchial asthma. All children were treatment-naive, and almost half of them (47.6%) were infected with genotype 1b. The advancement of liver disease by noninvasive elastography was assessed in 36 children, with half of them showing no fibrosis. Antiviral therapy was completed in all patients as planned, and the cure rate in the per-protocol population was 100% (39\/39). Three girls were considered lost to follow-up. Adverse events were rare and mild, occurring only in the oldest group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Eight-week GLE\/PIB therapy in children is well tolerated and highly effective in all age ranges regardless of gender. Its use in routine clinical practice will bring the ambitious goal of eliminating HCV worldwide a step closer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000005069","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T05:01:01Z","timestamp":1763614861000},"page":"445-449","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pangenotypic Glecaprevir\/Pibrentasvir Therapy for Chronic Hepatitis C in Children"],"prefix":"10.1097","volume":"45","author":[{"given":"Ma\u0142gorzata","family":"Paw\u0142owska","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, Toru\u0144"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Zar\u0119bska-Michaluk","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Allergology, Jan Kochanowski University, Kielce"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0352-9893","authenticated-orcid":false,"given":"Krystyna","family":"Dobrowolska","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Allergology, Jan Kochanowski University, Kielce"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justyna","family":"Moppert","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium Medicum Bydgoszcz, Nicolaus Copernicus University, Toru\u0144"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzanna","family":"Kalinowska","sequence":"additional","affiliation":[{"name":"Observation and Infectious Diseases Department for Children, St. Wojciech Hospital, COPERNICUS Podmiot Leczniczy Sp. z o.o., Gda\u0144sk"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Pokorska-\u015apiewak","sequence":"additional","affiliation":[{"name":"Department of Children\u2019s Infectious Diseases, Medical University of Warsaw, Warsaw"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mania","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Child Neurology, Institute of Paediatrics, Poznan University of Medical Sciences, Poznan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Majda-Stanis\u0142awska","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Medical University of Lodz, Lodz"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Flisiak","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Hepatology, Medical University of Bia\u0142ystok, Bia\u0142ystok, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"R2-20260410","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S2468-1253(19)30046-9","article-title":"Hepatitis C virus infection in children and adolescents.","volume":"4","author":"Indolfi","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R3-20260410","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S2468-1253(19)30385-1","article-title":"Global prevalence of hepatitis C virus in children in 2018: a modelling study.","volume":"5","author":"Schmelzer","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R4-20260410","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3748\/wjg.v27.i12.1117","article-title":"Cascade of care for children and adolescents with chronic hepatitis C.","volume":"27","author":"Rogers","year":"2021","journal-title":"World J Gastroenterol"},{"key":"R5-20260410","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1093\/jpids\/piae070","article-title":"Overview of hepatitis C in pregnancy: screening, management, and treatment.","volume":"13","author":"Rios","year":"2024","journal-title":"J. Pediatric Infect. Dis. Soc"},{"key":"R6-20260410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/ceh.2023.125957","article-title":"Recommendations of the Polish group of experts for HCV for the treatment of hepatitis C in 2023.","volume":"9","author":"Tomasiewicz","year":"2023","journal-title":"Clin Exp Hepatol"},{"key":"R7-20260410","doi-asserted-by":"crossref","first-page":"e200","DOI":"10.1016\/S2666-5247(20)30062-8","article-title":"Ledipasvir plus sofosbuvir in pregnant women with hepatitis C virus infection: a phase 1 pharmacokinetic study.","volume":"1","author":"Chappell","year":"2020","journal-title":"Lancet Microbe"},{"key":"R8-20260410","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1093\/cid\/ciae595","article-title":"Sofosbuvir\/velpatasvir pharmacokinetics, safety, and efficacy in pregnant people with hepatitis C virus.","volume":"80","author":"Chappell","year":"2025","journal-title":"Clin Infect Dis"},{"key":"R9-20260410","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31841","article-title":"Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in children with chronic HCV: part 2 of the DORA study.","volume":"74","author":"Jonas","year":"2021","journal-title":"Hepatology"},{"key":"R10-20260410","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.30840","article-title":"Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study.","volume":"71","author":"Jonas","year":"2020","journal-title":"Hepatology"},{"key":"R11-20260410","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/jpn3.12045","article-title":"Sofosbuvir\u2013velpatasvir in children 3\u201317 years old with hepatitis C virus infection.","volume":"78","author":"Jonas","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R12-20260410","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.30830","article-title":"Ledipasvir\u2010sofosbuvir for 12 weeks in children 3 to <6 years old with chronic hepatitis C.","volume":"71","author":"Schwarz","year":"2020","journal-title":"Hepatology"},{"key":"R13-20260410","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/jvh.12373","article-title":"Cognitive function and endogenous cytokine levels in children with chronic hepatitis C.","volume":"22","author":"Abu Faddan","year":"2015","journal-title":"J Viral Hepat"},{"key":"R14-20260410","doi-asserted-by":"crossref","first-page":"ciad319","DOI":"10.1093\/cid\/ciad319","article-title":"Hepatitis C guidance 2023 update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection.","author":"Bhattacharya","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R16-20260410","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/TCRM.S326099","article-title":"Profile of sofosbuvir and velpatasvir combination in the treatment of chronic hepatitis C in children and adolescents: current evidence.","volume":"20","author":"Brigham","year":"2024","journal-title":"Ther Clin Risk Manag"},{"key":"R17-20260410","doi-asserted-by":"crossref","first-page":"e16180","DOI":"10.1111\/liv.16180","article-title":"Effectiveness and safety of glecaprevir\/Pibrentasvir in Italian children and adolescents with chronic hepatitis C: a real\u2010word, multicenter study.","volume":"45","author":"Stinco","year":"2025","journal-title":"Liver Int"},{"key":"R18-20260410","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00535-023-01968-x","article-title":"Real-world efficacy and safety of glecaprevir\/pibrentasvir in Japanese adolescents with chronic hepatitis C: a prospective multicenter study.","volume":"58","author":"Mizuochi","year":"2023","journal-title":"J Gastroenterol"},{"key":"R19-20260410","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00431-013-1954-2","article-title":"Polish 2012 growth references for preschool children.","volume":"172","author":"Ku\u0142aga","year":"2013","journal-title":"Eur J Pediatr"},{"key":"R21-20260410","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00431-010-1329-x","article-title":"Polish 2010 growth references for school-aged children and adolescents.","volume":"170","author":"Ku\u0142aga","year":"2011","journal-title":"Eur J Pediatr"},{"key":"R22-20260410","doi-asserted-by":"crossref","first-page":"1504678","DOI":"10.3389\/fpubh.2024.1504678","article-title":"Attitudes and perspectives of healthcare workers on treating chronic hepatitis C infection in children and adolescents.","volume":"12","author":"Malik","year":"2025","journal-title":"Front Public Health"},{"key":"R23-20260410","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/liv.15827","article-title":"Efficacy and safety of DAA in children and adolescents with chronic HCV infection: a systematic review and meta\u2010analysis.","volume":"44","author":"Indolfi","year":"2024","journal-title":"Liver Int"},{"key":"R24-20260410","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.3390\/jcm12216949","article-title":"Real-world efficacy and safety of an 8-week glecaprevir\/pibrentasvir regimen in children and adolescents with chronic hepatitis C\u2014results of a multicenter EpiTer-2 study.","volume":"12","author":"Pawlowska","year":"2023","journal-title":"J Clin Med"},{"key":"R25-20260410","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clinthera.2024.12.011","article-title":"Real-life efficacy and safety of glecaprevir\/pibrentasvir pediatric formulation for chronic hepatitis C infection in children aged 3 to 12 years: a case series of 6 patients.","volume":"47","author":"Musto","year":"2025","journal-title":"Clin Ther"},{"key":"R26-20260410","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0140-6736(25)00397-6","article-title":"Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990-2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021.","volume":"405","year":"2025","journal-title":"Lancet"},{"key":"R27-20260410","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1097\/MPG.0000000000002320","article-title":"Normal liver stiffness values in children: a comparison of three different elastography methods.","volume":"68","author":"Mjelle","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R28-20260410","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/MPG.0b013e31829206a0","article-title":"Application and limitations of transient liver elastography in children.","volume":"57","author":"Goldschmidt","year":"2013","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R29-20260410","doi-asserted-by":"crossref","first-page":"e70329","DOI":"10.1111\/liv.70329","article-title":"Pharmacokinetics, safety, efficacy and acceptability of daclatasvir plus sofosbuvir in young children with chronic HCV infection.","volume":"45","author":"Farrag","year":"2025","journal-title":"Liver Int"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T04:00:49Z","timestamp":1775793649000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000005069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005069","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}